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Early symptomatic Alzheimer disease
Magnetic resonance imaging
A B S T R A C T
Interest in understanding the roles of white matter (WM) inﬂammation and damage in the pathophysiology of
Alzheimer disease (AD) has been growing signiﬁcantly in recent years. However, in vivo magnetic resonance
imaging (MRI) techniques for imaging inﬂammation are still lacking. An advanced diﬀusion-based MRI method,
neuro-inﬂammation imaging (NII), has been developed to clinically image and quantify WM inﬂammation and
damage in AD. Here, we employed NII measures in conjunction with cerebrospinal ﬂuid (CSF) biomarker
classiﬁcation (for β-amyloid (Aβ) and neurodegeneration) to evaluate 200 participants in an ongoing study of
memory and aging. Elevated NII-derived cellular diﬀusivity was observed in both preclinical and early symp-
tomatic phases of AD, while disruption of WM integrity, as detected by decreased fractional anisotropy (FA) and
increased radial diﬀusivity (RD), was only observed in the symptomatic phase of AD. This may suggest that WM
inﬂammation occurs earlier than WM damage following abnormal Aβ accumulation in AD. The negative cor-
relation between NII-derived cellular diﬀusivity and CSF Aβ42 level (a marker of amyloidosis) may indicate that
WM inﬂammation is associated with increasing Aβ burden. NII-derived FA also negatively correlated with CSF t-
tau level (a marker of neurodegeneration), suggesting that disruption of WM integrity is associated with in-
creasing neurodegeneration. Our ﬁndings demonstrated the capability of NII to simultaneously image and
quantify WM cellularity changes and damage in preclinical and early symptomatic AD. NII may serve as a
clinically feasible imaging tool to study the individual and composite roles of WM inﬂammation and damage in
AD.
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Alzheimer disease (AD) leads to impaired memory and cognition
culminating in dementia, loss of independence, and a heavy toll on
patients and their families. A large body of evidence has supported the
“amyloid hypothesis” that dysregulation of Aβ metabolism and the
associated aggregation of Aβ into amyloid plaque leads to a patho-
physiological process that results in synaptic dysfunction and neuronal
death. Thus, numerous therapies speciﬁcally targeting Aβ have been
tested in the past two decades (Blennow et al., 2010). However,> 100
candidate treatment compounds have failed to meet their clinical
endpoints, leading to increasing interest in other possible AD-related
pathophysiological mechanisms, such as accumulation of intracellular
tau (Brier et al., 2016; Fagan et al., 2011; Gordon et al., 2016; Johnson
et al., 2016), and more recently, inﬂammation (Heneka et al., 2015;
Holtzman et al., 2012; Jarrott and Williams, 2016; Leyns et al., 2017;
Suarez-Calvet et al., 2016).
Several lines of evidence point to the involvement of inﬂammation
and white matter (WM) damage in early AD disease progression. First,
cognitively normal individuals who chronically use non-steroidal anti-
inﬂammatories have fewer activated microglia and lower risk of AD
than non-users (Andersen et al., 1995; Broe et al., 2000; Cote et al.,
2012). Fibrillar Aβ stimulates a classical proinﬂammatory response in
microglia, which can be visualized in AD patients and may be present in
preclinical AD (Bradshaw et al., 2013; Serrano-Pozo et al., 2013; Ulrich
et al., 2018). A study of autosomal dominant AD suggested that astro-
cyte activation occurs in presymptomatic AD, indicating that in-
ﬂammatory astrocytosis may contribute to early symptomatic AD pa-
thology (Scholl et al., 2015). Moreover, disrupted WM may occur very
early in preclinical AD (Heise et al., 2011; Molinuevo et al., 2014;
Racine et al., 2014), promote phagocytosis of amyloid plaques (Smith
et al., 2007a; Stokin et al., 2005), and modulate the relationship be-
tween the pathological and clinical manifestations of AD (Salat et al.,
2009). Animal studies have recently demonstrated defective clearance
of myelin debris, axonal dystrophy, and oligodendrocyte reduction in
the triggering receptor expressed on myeloid cell 2 (TREM2 )–deﬁcient
mice compared to wild-type mice (Cantoni et al., 2015; Poliani et al.,
2015), suggesting microglial response to WM damage. These ﬁndings
have led to a search for accurate and robust in vivo markers speciﬁc for
inﬂammation and WM damage in AD.
A novel multi-parametric diﬀusion MRI analytic technique, diﬀu-
sion basis spectrum imaging (DBSI), was developed to simultaneously
detect and quantify inﬂammation and WM damage in the central ner-
vous system. In particular, DBSI can discretely quantify intra- and ex-
tracellular water and allows for discrimination of vasogenic edema,
increased cellularity, axonal injury/loss, and demyelination (Chiang
et al., 2014; Wang et al., 2014; Wang et al., 2011; Wang et al., 2015).
The DBSI biomarker for inﬂammation is the DBSI restricted water
compartment, which is a surrogate for cellularity. DBSI cellularity in-
creases have been associated with activated microglia and astrogliosis
in multiple sclerosis (Chiang et al., 2014; Wang et al., 2014; Wang et al.,
2011; Wang et al., 2015); therefore, it can be potentially employed as a
marker for astrogliosis and microglial activation in AD. Moreover, DBSI
can separate anisotropic diﬀusion markers (reﬂecting WM integrity)
from isotropic diﬀusion markers, and are thus more speciﬁc and ac-
curate in reﬂecting WM pathology than the standard model of diﬀusion
tensor imaging (DTI) (Chiang et al., 2014; Wang et al., 2014; Wang
et al., 2011; Wang et al., 2015). As initially conceived, DBSI employed
diﬀusion MRI scans with 99 diﬀusion weightings. This protocol is not
always available or optimal in clinical or clinical research settings. In
the previous simulation and ex vivo study (Chiang et al., 2014), a
compact 25-direction diﬀusion MRI scan provided suﬃcient accuracy
in DBSI solutions. Here, we use the same 25-direction, multiple b-value
diﬀusion MRI version of DBSI; We denote this clinical version of DBSI as
neuro-inﬂammation imaging (NII). NII was used to study healthy cog-
nitively normal controls, participants with preclinical (asymptomatic)
AD, and participants with early symptomatic AD to better understand
the role of WM inﬂammation and degeneration in the pathogenesis and
progression of AD. The association between NII-derived indices and CSF
biomarkers of AD pathology were examined to assess the relationship
between WM inﬂammation, damage and AD Aβ and tau pathologies.
2. Materials and methods
2.1. Participants
Two hundred participants were enrolled in longitudinal clinical and
biomarker studies of memory and aging at the Knight Alzheimer's dis-
ease Research Center at Washington University School of Medicine, St
Louis, MO, USA (P50AG005681, P01AG026276, and P01AG003991).
Details of recruitment and assessment have been published elsewhere
(Berg et al., 1998). The Human Research Protection Oﬃce at Wa-
shington University approved all studies, and written informed consent
was obtained from all participants. All individuals were evaluated by
experienced clinicians using a semi-structured interview with a
knowledgeable collateral source. Detailed neurological examinations of
the participants were performed in accordance with the Uniform Data
Set protocol of the National Alzheimer's Coordinating Center (Morris
et al., 2006). A clinical diagnosis of symptomatic AD, where appro-
priate, was made in accordance with criteria developed by working
groups from the National Institute on Aging and the Alzheimer's Asso-
ciation (Albert et al., 2011; McKhann et al., 2011). Dementia was
staged according to the global Clinical Dementia Rating, CDR (Morris,
1993). The inclusion criteria required participants have CSF measures
of amyloid (Aβ42) and neurodegeneration (total tau [t-tau]) within two
years of the MRI acquisition; Participants were classiﬁed as healthy
controls (n=140) if they were AD biomarker negative (CSF
Aβ42≥ 459 pg/ml and t-tau<339 pg/ml) as deﬁned previously (Vos
et al., 2013) and cognitively normal deﬁned as a CDR=0 (Morris,
1993). Participants were classiﬁed as preclinical AD (n=34) according
to NIA-AA criteria (Sperling et al., 2011) if they had positive CSF Aβ42
(CSF Aβ42 < 459 pg/ml) with normal cognition (CDR=0). Early
symptomatic AD participants (n=26) had very mild dementia
(CDR=0.5), positive CSF Aβ42 (CSF Aβ42 < 459 pg/ml) and these
participants were diagnosed with dementia thought to be due to AD
without other disease contribution, e.g., depression, cerebrovascular
disease, etc. (McKhann et al., 2011). Other neuropsychological eva-
luations including the Mini-Mental Stage Exam (MMSE) and CDR sum
of boxes were also provided.
2.2. Genotyping
DNA was extracted from peripheral blood samples by standard
procedures. Apolipoprotein E genotyping was performed as previously
described (Talbot et al., 1994). The presence of at least one apolipo-
protein E ε4-allele was deﬁned as APOE ε4 positive (APOE ε4+).
2.3. CSF collection and analysis
CSF (20–30ml) was collected within 24months of the imaging
session by routine lumbar puncture using a 22-gauge atraumatic
Sprotte spinal needle (Pajunk Medical Systems, Norcross, GA, USA)
after overnight fasting as previously described (Fagan et al., 2006).
Samples were gently inverted to avoid possible gradient eﬀects, brieﬂy
centrifuged at low speed, aliquoted (0.5 ml) into polypropylene tubes,
and frozen at−84 °C. Samples were analyzed by ELISA for Aβ42 and t-
tau (INNOTEST; Fujirebio, formerly Innogenetics, Ghent, Belgium).
2.4. MRI acquisition
Diﬀusion MRI was collected on 3 T TIM Trio (Siemens, Erlangen,
Germany) scanners with a 12-channel head coil equipped with parallel
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imaging. The imaging resolution was 2×2×2mm3. Repetition time
(TR) and echo time (TE) were 14,500ms and 112ms, respectively. The
25-direction diﬀusion-encoding scheme (24 diﬀusion sensitized +1
unsensitized [B0] volumes) was implemented for data acquisition. The
maximal b-value was 1400 s/mm2. The full set of b-table is presented in
Supplementary Table 3. Data were collected in two 6-min runs using a
single-shot diﬀusion-weighted echo planar imaging sequence.
Diﬀusion-weighted images were registered to T1-weighted (T1W)
magnetization prepared rapid acquisition gradient echo (MPRAGE) and
T2-weighted (T2W) fast spin echo (T2W-FSE) scans. The acquisition
parameters for MPRAGE were the following: TR, 2400ms; TE, 3.16ms;
inversion time, 1000ms; imaging resolution, 1× 1×1mm3. T2W-FSE
was acquired with the following parameters: TR, 3200ms; TE, 455ms;
imaging resolution, 1×1×1mm3.
2.4.1. Neuro-inﬂammation imaging
In neuro-inﬂammation imaging (NII), each of the potential patho-
logical components, including inﬂammatory cell components, extra-
cellular water/vasogenic edema, neuronal injury/loss, and demyelina-
tion, within each voxel is modeled by a dedicated diﬀusion tensor
(Supplementary Fig. 1). The weighted sum of all sub-voxel pathological
components describes the composition of pathological components as
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Speciﬁcally, NII models the entire diﬀusion-weighted MR signal as a
linear combination of multiple anisotropic diﬀusion tensors (the ﬁrst
term in Eq. [1], representing crossing myelinated and unmyelinated
axons of varied directions) and a spectrum of isotropic diﬀusion com-
ponents (the second term, resulting from cells, sub-cellular structure,
and edematous water). The quantities Sk and
⎯→⎯b| |k are the signal and b-
value of the kth diﬀusion gradient, NAniso is the number of anisotropic
tensors (ﬁber tracts), Ψik is the angle between the kth diﬀusion gradient
and the principal direction of the ith anisotropic tensor, λ‖_i and λ⊥_i are
the axial and radial diﬀusivities of the ith anisotropic tensor, fi is the
signal intensity fraction for the ith anisotropic tensor, and a and b are
the low and high diﬀusivity limits for the isotropic diﬀusion spectrum f
(D) (reﬂecting cellularity and edema). Similarly to DBSI (Wang et al.,
2011; Wang et al., 2015), a two-step approach was employed to solve
Eq. 1. In the ﬁrst step, the number of anisotropic tensors (NAniso) and
associated principal directions (Ψik) were determined based on a dif-
fusion bases decomposition approach (Ramirez-Manzanares et al.,
2007). The second step was performed to determine λ‖_i λ⊥_i and fi of
each anisotropic tensor (i=1, 2 … NAniso) along with the isotropic
diﬀusion spectrum f(D) in Eq. (1) using a regularized least-squares cost
function (Wang et al., 2011; Wang et al., 2015). Diﬀusion measure-
ments with multiple directions and weightings are required for NII to
provide a unique solution (Scherrer and Warﬁeld, 2010; Scherrer and
Warﬁeld, 2012). Regularized nonnegative least-squares analysis in-
corporating a priori information of nonnegative signal intensities frac-
tion (Scherrer and Warﬁeld, 2012) and ﬁnite signal energy (Borgia
et al., 1998; Borgia et al., 2000) are employed to prevent over-ﬁtting to
the noisy data while retaining the accuracy of the NII solution. By
solving the NII model, the following indices were quantiﬁed: (1) cel-
lular fraction (reﬂecting cell density); (2) cellular diﬀusivity (reﬂecting
cell size); (3) FA (reﬂecting the WM integrity); (4) axial diﬀusivity
(reﬂecting WM axonal injury); (5) radial diﬀusivity (reﬂecting WM
demyelination); and (6) mean diﬀusivity (the average of axial and ra-
dial diﬀusivities). In particular, we deﬁne the isotropic diﬀusion com-
ponents to represent restricted isotropic diﬀusion (associated with
cellular components) by using a tentative threshold for isotropic dif-
fusivity of 0.3 μm2/ms, based on previous ﬁndings (Wang et al., 2011;
Wang et al., 2015). Unlike DTI and other advanced diﬀusion MRI
approaches, NII can detect and quantify the unique restricted isotropic
signal signature reﬂecting inﬂammatory cells by excluding the con-
founding eﬀects from anatomical complexity and WM degeneration.
2.5. Data processing and analysis
The 25 diﬀusion-weighted images acquired in one diﬀusion MRI
sequence were motion-corrected by an iterative procedure. In order to
correct for eddy current related geometric distortion between EPI dif-
fusion images and 3D GRE/FSE anatomical images, we ﬁrst registered
the non-b0 diﬀusion images to b0 images with rigid body transforma-
tion. Then a 9-parametric aﬃne transformation was employed to cor-
rect for stretch along the phase encode direction to better align the b0
image to the T2W image. Registration was completed by aligning the
T2W images to the T1W images which were then aligned with the atlas
image. The ﬁnal resampling step output 24 volumes registered with the
B0 volume of the ﬁrst acquired diﬀusion-weighted imaging dataset. The
two runs were averaged together to obtain a better signal-to-noise ratio.
All datasets were analyzed by a multi-tensor model analysis package
developed in-house (Wang et al., 2011) in MATLAB (MathWorks) and
maps of NII cellular fraction, cellular diﬀusivity, FA, axial, radial and
mean diﬀusivities were generated.
The whole-brain, voxel-wise NII-derived indices were analyzed
using Tract Based Spatial Statistics (TBSS) from the FSL (http://www.
fmrib.ox.ac.uk/fsl) software package (Smith et al., 2007b; Smith and
Nichols, 2009). NII FA images were slightly eroded, so the boundary
image slices were excluded to remove possible outliers caused by poor
diﬀusion tensor ﬁtting at the edges. Participants' FA data were aligned
into a common space using the nonlinear registration tool FNIRT
(Jenkinson et al., 2002). A mean FA image was created and thinned to
create a mean FA skeleton that represents the centers of all tracts
common to the group. Each participant's aligned FA data, and other NII-
derived indices, were projected onto this skeleton for statistical ana-
lyses. Nonparametric permutation tests were used for voxel-wise sta-
tistical analysis of the individual FA skeletons between the healthy
controls, the preclinical AD and the early symptomatic AD cohorts.
Voxel-wise associations between NII-derived indices and CSF markers
of AD pathologies (CSF Aβ42 and t-tau) were examined through TBSS.
The signiﬁcance threshold for group diﬀerences and associations with
CSF biomarkers was set at P < .05, corrected for multiple comparisons
by using a family-wise error correction across voxels by using the
threshold-free cluster-enhancement option in Randomise 2.0 in FSL
(Smith and Nichols, 2009). Identiﬁcation of the abnormal WM tracts
revealed by TBSS was based on the Johns Hopkins University (JHU)
atlas (Hua et al., 2008; Mori and van Zijl, 2007; Wakana et al., 2004;
Wakana et al., 2007). The statistical analyses performed by TBSS con-
trolled for age, gender, and the presence of an APOE ε4 allele.
Continuous and categorical variables in characteristics across all the
three groups were compared using the Kruskal-Wallis test and the Chi-
square test, respectively. The least square means per group for each
outcome were estimated after controlling for age, gender and APOE ε4
genotype. The partial correlation was also considered to measure the
strength of a relationship between CSF measures and imaging metrics in
WM tracts while controlling for the eﬀects of other variables. All sta-
tistical tests were two-sided with α=0.05. SAS version 9.4 (Cary, NC)
was used to perform all statistical analyses.
3. Results
3.1. Participant demographics
Demographic data are summarized in Table 1. Our cohort included
140 cognitively normal healthy control participants (CDR=0.5, CSF
Aβ42-negative), 34 cognitively normal individuals with preclinical AD
(CDR=0.5, CSF Aβ42-positive), and 26 participants with early symp-
tomatic AD (CDR=0.5, CSF Aβ42-positive). On average, the early
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symptomatic AD individuals were signiﬁcantly older than the healthy
controls and preclinical AD individuals, and the early symptomatic AD
group included more male participants than the other two cohorts. Only
12.9% of the healthy controls carried at least one APOE ε4 allele,
whereas 76.5% of the preclinical AD and 88.5% of the early sympto-
matic AD participants carried this allele. MMSE and CDR sum of box
measures for early symptomatic AD were signiﬁcantly higher than
those in the healthy controls and preclinical AD group. The CSF level of
Aβ42 in the healthy controls was signiﬁcantly higher than that in the
preclinical and early symptomatic AD. The CSF level of t-tau was sig-
niﬁcantly elevated in the early symptomatic AD, while no diﬀerence
was seen between the healthy controls and the preclinical AD partici-
pants.
3.2. NII cellular fraction in the preclinical and early symptomatic AD
No voxel-wise statistical diﬀerences of the NII cellular fraction (re-
ﬂecting cell density) were found among the healthy controls, the pre-
clinical, and the early symptomatic AD cohorts. As an example, the
averaged NII cellular fraction in the region of genu of corpus callosum is
4.5% (±1.1%) for the healthy controls, 4.5% (±0.8%) for the pre-
clinical AD and 4.4% (±1.3%) for the early symptomatic AD.
3.3. NII cellular diﬀusivity in the preclinical and early symptomatic AD
Elevated NII cellular diﬀusivity (reﬂecting cell size) was observed in
the preclinical AD cohort when compared to the healthy controls in the
major WM tracts including corpus callosum, internal capsule, corona
radiata and cingulum etc. (Fig. 1A). NII cellular diﬀusivity was also
signiﬁcantly increased in the early symptomatic AD cohort when
compared to those in the preclinical AD in some major WM tracts
(Fig. 1B). As an example, the signiﬁcant voxels common to all partici-
pants in the genu of corpus callosum were extracted to demonstrate
signiﬁcantly increasing NII cellular diﬀusivity in the preclinical AD
when compared to the healthy controls, and the further increasing of
this index in the early symptomatic AD cohort (P < .05) (Fig. 1C).
Similar ﬁndings were also found in other white matter tracks and
summarized in Supplementary Table 1.
3.4. Relationship between NII biomarker of inﬂammation and CSF
biomarker of amyloid plaque
NII cellular diﬀusivity was negatively correlated with CSF levels of
Aβ42 in major WM tracts (Fig. 2A and Supplementary Table 2) when
analyzed across all groups. The mean NII cellular diﬀusivity from the
cluster located in the genu of corpus callosum were extracted. As an
estimate of eﬀect size, the partial correlations were also examined be-
tween NII imaging markers and CSF Aβ42. When controlling with age,
gender and APOE ε4 genotype, the partial correlation with CSF Aβ42
was rpartial=−0.39 (P < .001) for NII cellular diﬀusivity.
3.5. NII-derived FA, axial, radial and mean diﬀusivities in the preclinical
and early symptomatic AD
A signiﬁcant voxel-wise decrease of NII FA was found in the early
symptomatic AD cohort when compared to the healthy controls and the
preclinical AD cohorts in most of the WM tracts (Fig. 3A & B and
Supplementary Table 1). The signiﬁcant voxel-wise increase of NII ra-
dial diﬀusivity, which is a more accurate measure of the myelination
than its DTI-derived counterpart (Wang et al., 2011; Wang et al., 2015),
was also found in the early symptomatic AD cohort when compared to
the healthy controls and the preclinical AD cohorts in most of the WM
tracts (Fig. 3C & D and Supplementary Table 1). There were no dif-
ferences of NII FA and radial diﬀusivity between the healthy controls
and the preclinical AD cohorts. The signiﬁcant voxels common to all
participants in the genu of corpus callosum were extracted to demon-
strate there were a signiﬁcant decrease of NII-derived FA (Fig. 3E. (a)
and a signiﬁcant increase of NII radial diﬀusivity (Fig. 3E. (b) in the
early symptomatic AD cohort when compared to the healthy controls
and the preclinical AD cohorts (P < .05). No diﬀerences were found
among the three cohorts for NII axial and mean diﬀusivities.
3.6. Relationship between NII-derived indices and CSF t-tau
A signiﬁcant negative relationship was found between CSF levels of
t-tau and NII FA in WM (Fig. 4A and Supplementary Table 2). No other
NII-derived indices were associated with CSF levels of t-tau. The partial
correlations as a measure of eﬀect size were also examined between NII
FA and CSF tau in those voxels that were signiﬁcant in the splenium of
corpus callosum. When controlling for age, gender and APOE ε4 gen-
otype, the partial correlation with CSF t-tau was rpartial=−0.33
(P < .001) for NII FA.
4. Discussion
Immune cells, particularly microglia and astrocytes, have been re-
ported to mediate the inﬂammatory response in AD and are considered
a signiﬁcant contributor to AD pathogenesis. Detecting and quantifying
the early neuroinﬂammation manifested in AD as immune cell activa-
tion and inﬁltration could shed light on potential mechanisms under-
lying AD pathogenesis and progression. Based on the previous success
of DBSI (Chiang et al., 2014; Wang et al., 2014; Wang et al., 2011;
Table 1
Characteristics of study participants.
Characteristics Healthy controls Preclinical AD Early symptomatic AD P-value
n 140 34 26
Clinical dementia rating (CDR) 0 0 0.5
Age, years 61.1 ± 8.1 62.6 ± 7.0 75.0 ± 5.7 < 0.001
Male sex 53 (37.9%) 11(32.4%) 16 (61.5%) 0.0468
APOE e4 + 18 (12.9%) 26 (76.5%) 23 (88.5%) < 0.001
MMSE 29.4 ± 0.9 29.3 ± 1.3 25.5 ± 2.7 < 0.001
CDR-sumbox 0.0 ± 0.1 0.0 ± 0.0 2.7 ± 1.0 < 0.001
CSF Aβ42 (pg/ml) 786.1 ± 200.7 375.3 ± 76.1 325.1 ± 71.9 < 0.001
CSF t-tau (pg/ml) 206.9 ± 61.2 228.8 ± 101.8 507.4 ± 240.6 < 0.001
Data are presented as mean (SD) or number (%).
Healthy controls: participants with ≥459 pg/ml Aβ42 and≤ 339 pg/ml total tau in the cerebrospinal ﬂuid (CSF) and with normal cognition (CDR=0).
Preclinical AD: participants with<459 pg/ml Aβ42 in the CSF and with normal cognition (CDR=0).
Early symptomatic AD: participants with< 459 pg/ml Aβ42 in the CSF and with very mild AD dementia (CDR=0.5).
APOE ε4 +, positive for at least one apolipoprotein E ε4-allele.
MMSE: Mini-Mental State Exam.
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Wang et al., 2015), NII was developed and implemented on clinical
scanners to simultaneously detect and quantify WM cellularity change,
which may reﬂect inﬂammation and WM damage, and their associa-
tions with CSF measures of AD pathologies in preclinical and early
symptomatic AD.
Currently, three major types of biomarkers of inﬂammation in AD
have been evaluated, but none have proved ideal. First, PET tracers
such as [11C]-(R)-PK11195, [11C]-PBR28, [11C]-DPA-713, [18F]-DPA-
714, [18F]-FEPPA, which target the 18 kDa translocator protein (TSPO)
(a marker for neuroinﬂammation), are used for imaging of microglia
activation and inﬂammation in AD animal models and patients
(Abourbeh et al., 2012; Chauveau et al., 2009; Hamelin et al., 2016b;
Schuitemaker et al., 2013; Suridjan et al., 2015). Okello et al. found
that activated microglia labeled by increased [11C]-(R)-PK11195
binding was observed in prodromal participants with increased Pitts-
burgh compound B ([11C]-PIB) retention for Aβ plaque load in brain
(Okello et al., 2009). Another study found elevated microglial
activation, as labeled by high [11C]-(R)-PK11195 binding, in a group of
AD subjects with high [11C]-PIB retention (Edison et al., 2008). How-
ever, these PET approaches are limited by issues including binding tied
to genetic polymorphisms (Owen et al., 2011; Owen et al., 2012),
lackingspeciﬁcity of translocator protein binding for activated micro-
glia (Kreisl et al., 2013; Lavisse et al., 2012) and variability of plasma
protein binding (Turkheimer et al., 2015). Additionally, most of the
current TSPO PET tracers are [11C] based and can only be performed at
academic centers in proximity to a research cyclotron facility (Fan
et al., 2015; Varley et al., 2015). Elevated levels of CSF YKL40 (Craig-
Schapiro et al., 2010) and other proteins have also been reported to be
markers of inﬂammation (Alcolea et al., 2015; Heppner et al., 2015;
Wilkins et al., 2015). Astroglial activation suggested by the elevated
CSF levels of YKL40 has been observed in preclinical AD, mild cognitive
impairment and early AD (Alcolea et al., 2015; Antonell et al., 2014;
Craig-Schapiro et al., 2010; Olsson et al., 2013). CSF levels of YKL40 are
promising in discriminating between cognitively normal individuals
Fig. 1. Neuro-inﬂammation imaging (NII) detects
increased cellular diﬀusivity in the preclinical AD
and in the early symptomatic AD when compared to
the healthy control participants. Coronal, axial and
sagittal views show the voxels (red/yellow clusters,
expanded to be visible) in which NII cellular diﬀu-
sivity (reﬂecting cell size) signiﬁcantly (P < .05)
increased (1) in preclinical AD after multiple com-
parison when compared to the healthy controls co-
hort (A) and (2) in the early symptomatic AD cohort
when compared to the preclinical AD cohorts (B).
The mean FA skeleton (green) representing the cen-
ters of all WM tracts common to participants was
overlaid on the Montreal Neurological Institute
standard space brain T1-weighted image. (C) Boxplot
demonstrates that the NII cellular diﬀusivity in the
region of genu of corpus callosum is signiﬁcantly
increased in the preclinical AD and further sig-
niﬁcantly increased in the early symptomatic AD
when compared to that in the healthy controls. Thick
lines indicate means, boxes indicate 25th to 75th
percentiles, and thin lines indicate 5th and 95th
percentiles. The age, gender, and APOE e4 genotype
were controlled for in computing the statistical sig-
niﬁcance of diﬀerences. L, left hemisphere; R, right
hemisphere; P, posterior; A, anterior; *P < .05. (For
interpretation of the references to color in this ﬁgure
legend, the reader is referred to the web version of
this article.)
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and patients with mild cognitive impairment (MCI) and AD, and in
predicting the progression of cognitively normal individuals to MCI
(Kester et al., 2015). However, CSF analyses have limitations including
potential assay drift (Schindler et al., 2018), inter-laboratory variability
in measurements of certain markers (Mattsson et al., 2010; Mattsson
et al., 2011; Mattsson et al., 2013), the invasiveness of a lumbar
puncture and an inability to provide information about the anatomic
location of pathology (Zetterberg, 2015). Given these limitations, as a
non-invasive, non-radioactive imaging technique capable of quanti-
fying cellular alterations which may reﬂect inﬂammation in the general
population, NII holds a unique position to potentially advance our
understanding of the role of inﬂammation in pre-symptomatic and early
symptomatic AD.
In the present study, the lack of statistical diﬀerence of the NII
cellular fraction among healthy controls, preclinical and early symp-
tomatic AD suggests that there is no increase in inﬂammatory cell
fraction (whether from proliferation or inﬁltration) in preclinical and
early symptomatic AD. Microglia/astrocyte activation involves a rapid
alteration of cellular metabolism and function, which can be accom-
panied by a graded spectrum of morphological changes that transform
highly ramiﬁed microglia/astrocytes into amoeboid-phagocytic micro-
glia/astrocytes with an increase in cell body size (Iaccarino et al., 2016;
Soltys et al., 2001; Torres-Platas et al., 2014). A few diﬀusion MRI
techniques have demonstrated their sensitivity to ﬁber or cell diameters
by tracking the changes of water diﬀusion (Alexander et al., 2010;
Barazany et al., 2009; Schachter et al., 2000; Stanisz et al., 1997). In-
creased cellular diﬀusivity which would be correspond with an increase
in cell body size may serve as a potential marker for microglia/astrocyte
activation in AD. In this study, NII derived cellular diﬀusivity was
quantiﬁed in each group to reﬂect the extent of activated microglia/
astrocytes. The observed increase of NII cellular diﬀusivity (Fig. 1) in
the preclinical AD and early symptomatic AD group may suggest the
microglia/astrocyte activation.
Emerging studies have demonstrated that microglial activation can
promote Aβ clearance and play important role in neuroprotection
during the early stage of AD (Gandy and Heppner, 2013; Solito and
Sastre, 2012; Yang et al., 2011). The observed increase of NII cellular
diﬀusivity (Fig. 1) and absence of WM damage according to NII-derived
FA and radial diﬀusivity ﬁndings (Fig. 3) in the preclinical stage suggest
the microglia/astrocyte activation may be the early pathological sig-
nature in AD. These results would be consistent with the neuroprotec-
tive role of early inﬂammation induced by Aβ. With progression of
disease, chronic inﬂammation may stimulate pro-inﬂammatory cyto-
kines and cause neuronal death (Czeh et al., 2011; Lucin and Wyss-
Coray, 2009). NII ﬁndings in symptomatic AD may indicate the pre-
sence of chronic WM inﬂammation (Fig. 1) accompanied by wide
spread WM damage, particularly myelin damage more than axonal in-
jury (Fig. 3). These results are consistent with previous PET studies
which found microglial activation in early preclinical AD to be pro-
tective (Hamelin et al., 2016a) and animals studies that have shown a
detrimental role of chronic inﬂammation and neuronal loss in the later
stage of AD (Leyns and Holtzman, 2017; Leyns et al., 2017; Wyss-Coray
and Mucke, 2002).
Previous cross sectional DTI studies on sporadic AD and MCI pa-
tients reported widespread WM damages indicated by reduced FA and
increased mean diﬀusivity (Agosta et al., 2011; Amlien and Fjell, 2014;
Birdsill et al., 2014; Bosch et al., 2012; Kantarci et al., 2017; Madhavan
et al., 2016; Sexton et al., 2011). Those WM regions include corpus
Fig. 2. Correlations between NII-derived indices and
CSF Aβ42. Coronal, axial and sagittal views show the
voxel-wise signiﬁcant (P < .05) (red/yellow clus-
ters, expanded to be visible) correlations between
NII cellular diﬀusivity and CSF Aβ42 (A). The mean
FA skeleton (green) representing the centers of all
WM tracts common to all participants was overlaid
on the Montreal Neurological Institute standard
space brain T1-weighted image. Cluster-based
thresholding corrected for multiple comparisons. (B)
Scatter plot showing the association between NII
cellular diﬀusivity and the CSF marker of β-amyloid
in the genu of the corpus callosum. Diamond marker
represents the healthy controls, red triangle re-
presents the preclinical AD and the green circle re-
presents the early symptomatic AD participants. The
age, gender and APOE ε4 genotype were controlled
for in computing the statistical signiﬁcance of dif-
ferences. L, left hemisphere; R, right hemisphere; P,
posterior; A, anterior. (For interpretation of the re-
ferences to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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callosum, internal capsule, corona radiata, cingulum, fornix, superior
longitudinal faciculus and superior fronto-occipital fasciculus, un-
cinated fasciculus etc., which largely overlap with the WM damage
regions detected by reduced NII FA and increased NII radial diﬀusivity.
WM microstructural changes have also been reported in aged adults
without dementia using free water elimination DTI (Hoy et al., 2017).
With more advanced modeling, NII detected increased cellular diﬀu-
sivity, unchanged FA and radial diﬀusivity in the genu, body and
splenium corpus callosum, internal capsule, corona radiata, posterior
thalamic radiation, external capsule, fornix, etc. (Supplementary
Table 1) in those with preclinical AD. Those ﬁndings may indicate WM
inﬂammation occurs earlier than WM damage following abnormal
Fig. 3. NII detects decreased FA and increased radial
diﬀusivity in the early symptomatic AD when com-
pared to preclinical AD and healthy controls.
Coronal, axial and sagittal views show the voxels
(red/yellow clusters, expanded to be visible) in
which (1) FA signiﬁcantly (P < .05) decreased in
early symptomatic AD after multiple comparison
when compared to the healthy controls (A) and the
preclinical AD (B) cohorts; (2) radial diﬀusivity sig-
niﬁcantly increased in the early symptomatic AD
cohort when compared to the healthy controls (C)
and the preclinical AD (D) cohorts. The mean FA
skeleton (green) representing the centers of all WM
tracts common to participants was overlaid on the
Montreal Neurological Institute standard space brain
T1-weighted image. (E) Boxplot demonstrates that,
in the region of genu of corpus callosum, the FA (a) is
signiﬁcantly decreased and radial diﬀusivity (b) is
signiﬁcantly increased in the early symptomatic AD
when compared to that in the preclinical AD and the
healthy controls cohorts. Thick lines indicate means,
boxes indicate 25th to 75th percentiles, and thin
lines indicate 5th and 95th percentiles. The age,
gender, and APOE ε4 genotype were controlled for in
computing the statistical signiﬁcance of diﬀerences.
L, left hemisphere; R, right hemisphere; P, posterior;
A, anterior; *P < .05. (For interpretation of the re-
ferences to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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amyloid accumulation in the preclinical AD period.
Abnormal amyloid deposition is considered an early AD pathology
preceding tau accumulation (Bateman et al., 2012; Fagan et al., 2014).
Fibrillar Aβ stimulates a classical proinﬂammatory response in micro-
glia, which can be visualized in AD patients and may be present in
preclinical AD (Bradshaw et al., 2013; Serrano-Pozo et al., 2013; Ulrich
et al., 2018). Our ﬁnding of a signiﬁcant correlation between NII WM
inﬂammation measure (cellular diﬀusivity) and CSF Aβ42 (Fig. 2A) is
consistent with previous histological examination of AD brains as well
as cell culture studies (Perlmutter et al., 1990), suggesting the WM
involvement of the Aβ stimulated neuroinﬂammation. In contrast, CSF
t-tau levels did not elevate in preclinical group and did not impact on
the early WM inﬂammation detected by NII. Cerebral Aβ deposition and
persistent activated microglia might both induce neuronal damage
(Morales et al., 2014; von Bernhardi et al., 2010), which has been
quantitatively measured by CSF t-tau. The observed association be-
tween CSF t-tau levels and NII WM damage measure in our cohort
suggests the WM involvement of the neurodegeneration process in early
symptomatic AD. The elevation of CSF Aβ42 levels in preclinical group
without NII-detected WM damage may suggest the delayed impact of
amyloid deposition on WM damage. Although the biological mechan-
isms still remain unknown, the diﬀerent associations between AD
hallmark pathologies and NII WM measures may suggest the distinct
impacts of amyloid deposition and neuroﬁbrillary tangles on WM in-
tegrity.
Widespread WM damage such as demyelination was observed and
associated with cognitive decline in individuals with symptomatic AD
(Nir et al., 2013; O'Dwyer et al., 2011; Stebbins and Murphy, 2009). In
this study, we found increased NII radial diﬀusivity and decreased NII
FA in multiple white matter tracks (Supplementary Table 1) in early
symptomatic AD, suggesting early involvement of demyelination and
WM damage. Signiﬁcant correlation between NII FA and CSF levels of t-
tau (Fig. 4) suggests that WM abnormalities become more severe with
increasing neurodegeneration.
The two tensor model (Pasternak et al., 2009) and other advanced
diﬀusion MRI models (Collier et al., 2018; Edwards et al., 2017; White
et al., 2013) have been previously proposed to eliminate the partial
volume eﬀect from free water, such as CSF, by including a free water
compartment. In comparison to previous diﬀusion MRI methods, NII
computes a spectrum of isotropic diﬀusion compartments to quantify
not only free water, but also restricted, hindered water compartments,
reﬂecting cellularity inﬁltration and edema, respectively, in CNS de-
generative diseases (Chiang et al., 2014; Wang et al., 2011; Wang et al.,
2015). In order to model the complex pathologies, NII employs a data-
driven multiple tensor platform to analyze diﬀusion signals and adap-
tively determine the number and properties of diﬀusion compartments
by solving an inverse problem.
Our previous studies have found that the accuracy and precision of
DBSI computation depends on the SNR of diﬀusion MRI images (Chiang
et al., 2014). From the Monte-Carlo simulation, no diﬀerence from the
true values for the DBSI derived metrics was observed using 25- and 99-
direction diﬀusion schemes. We found that a SNR larger than 30 should
Fig. 4. Correlations between NII-derived FA and CSF
tau. Coronal, axial and sagittal views show the voxel-
wise signiﬁcant (P < .05) (red/yellow clusters, ex-
panded to be visible) correlations between NII FA
and CSF t-tau (A) The mean FA skeleton (green) re-
presenting the centers of all WM tracts common to
all participants was overlaid on the Montreal
Neurological Institute standard space brain T1-
weighted image. Cluster-based thresholding cor-
rected for multiple comparisons. Scatter plots show
the correlation between NII-derived indices and the
CSF t-tau in the region of genu of corpus callosum
(B). Diamond marker represents the healthy controls,
red triangle represents the preclinical AD and the
green circle represents the early symptomatic AD
participants. The age, gender and APOE ε4 genotype
were controlled for in computing the statistical sig-
niﬁcance of diﬀerences. L, left hemisphere; R, right
hemisphere; P, posterior; A, anterior. (For inter-
pretation of the references to color in this ﬁgure le-
gend, the reader is referred to the web version of this
article.)
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be enough for DBSI computation. In our study, the averaged SNR in WM
for each diﬀusion MRI acquisition is 45 on b0 images. With two re-
petitions of diﬀusion MRI acquisition, SNR can reach 63 on b0 images,
which is suﬃcient for NII computation.
This study has several limitations. First, although NII has been va-
lidated for a diﬀerent neurodegeneration disease, MS, there are no di-
rect validations of NII's inﬂammation and WM damage indices in AD.
We plan to validate NII by comparing with histopathology studies of AD
autopsy brain, and other PET markers of inﬂammation such as DPA-
714, PBR28 (Wang et al., 2009), PK11195(Shah et al., 1994). Another
limitation is that new clinical neuropsychological tests such as Montreal
cognitive assessment is not available in this study. Future studies will be
needed to further clarify the level and types of cognitive impairment
and its relationship with NII measures in the symptomatic group. Fi-
nally, longitudinal clinical studies will be needed to determine the re-
levance of NII indices in prediction of cognitive outcomes. Despite these
limitations, our ﬁndings support NII's future applications to char-
acterize AD progression. Moreover, NII can be readily deployed on most
clinical MRI scanners and safely translated to clinical trials of larger
patient populations.
5. Conclusion
AD is typically considered a disease of the gray matter. However,
over the past several years, studies have reported abnormalities in
white matter that are associated with disease progression. This study
demonstrated that NII can simultaneously image and quantify WM
cellularity changes and damage in preclinical and early symptomatic
AD. With further validation and establishment, NII could be clinically
translated to noninvasively investigate the roles of WM inﬂammation
and damage in AD pathogenesis.
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